Zentalis Pharmaceuticals (ZNTL) Research & Development (2019 - 2026)

Zentalis Pharmaceuticals' Research & Development history runs 8 years deep, the most recent figure standing at $28.7 million for Q1 2026.

• On a quarterly basis, Research & Development rose 5.39% year-over-year to $28.7 million in Q1 2026; TTM through Mar 2026 was $108.8 million, a 25.21% decrease from a year earlier, with the FY2025 full-year figure at $107.3 million, down 36.05% from the prior year.
• Research & Development eased to $28.7 million in Q1 2026 per ZNTL's latest filing, from $29.5 million in the prior quarter.
• Across five years, Research & Development topped out at $51.6 million in Q4 2023 and bottomed at $23.0 million in Q3 2025.
• The 5-year median for Research & Development is $42.2 million (2022), against an average of $39.2 million.
• Across the five-year window, Research & Development grew 26.94% in 2023 and sank 45.05% in 2025, its largest moves.
• Year by year, Research & Development stood at $40.6 million in 2022, then rose by 26.94% to $51.6 million in 2023, then plunged by 36.05% to $33.0 million in 2024, then dropped by 10.57% to $29.5 million in 2025, then decreased by 2.62% to $28.7 million in 2026.
• Per Business Quant, the three latest ZNTL Research & Development figures stand at $28.7 million (Q1 2026), $29.5 million (Q4 2025), and $23.0 million (Q3 2025).